170 related articles for article (PubMed ID: 32895879)
1. Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome.
Pirhonen L; Gyllensten H; Fors A; Bolin K
Eur J Health Econ; 2020 Dec; 21(9):1317-1327. PubMed ID: 32895879
[TBL] [Abstract][Full Text] [Related]
2. Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial.
Pirhonen L; Bolin K; Olofsson EH; Fors A; Ekman I; Swedberg K; Gyllensten H
Pharmacoecon Open; 2019 Dec; 3(4):495-504. PubMed ID: 30825129
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of person-centred care provided to patients with chronic heart failure and/or chronic obstructive pulmonary disease.
Pirhonen L; Gyllensten H; Olofsson EH; Fors A; Ali L; Ekman I; Bolin K
Health Policy Open; 2020 Dec; 1():100005. PubMed ID: 37383310
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Jiang M; You JHS
Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
[TBL] [Abstract][Full Text] [Related]
5. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
8. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
[TBL] [Abstract][Full Text] [Related]
9. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Chin CT; Mellstrom C; Chua TS; Matchar DB
Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
[TBL] [Abstract][Full Text] [Related]
14. A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
Cui M; Tu CC; Chen EZ; Wang XL; Tan SC; Chen C
Adv Ther; 2016 Sep; 33(9):1600-11. PubMed ID: 27397588
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Gasche D; Ulle T; Meier B; Greiner RA
Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
[TBL] [Abstract][Full Text] [Related]
16. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
Coleman CI; Limone BL
Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
[TBL] [Abstract][Full Text] [Related]
17. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling.
Connock M; Stevens C; Fry-Smith A; Jowett S; Fitzmaurice D; Moore D; Song F
Health Technol Assess; 2007 Oct; 11(38):iii-iv, ix-66. PubMed ID: 17903392
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective.
Zhang L; Lin Z; Yin H; Liu J; Xuan J
Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579
[TBL] [Abstract][Full Text] [Related]
20. The impact of person-centred care on patients' care experiences in relation to educational level after acute coronary syndrome: secondary outcome analysis of a randomised controlled trial.
Wolf A; Vella R; Fors A
Eur J Cardiovasc Nurs; 2019 Apr; 18(4):299-308. PubMed ID: 30652920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
